Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abzena Enters ADC Master Services Agreement | Contract Pharma

What are you searching for?

Sign in
Videos

Abzena Enters ADC Master Services Agreement

The contract has a potential value of $5 million

By: Betsy Louda

, Contract Pharma



Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) towards clinical trials.

The development and GMP manufacturing of the ADC has a value of over $5 million. The services will be carried out mainly by Abzena’s chemistry and biomanufacturing groups in Bristol, PA and San Diego, CA.

Abzena has worked with the US-based company for a number of years, with the relationship built around Abzena’s chemistry services. Following the initial chemistry development, Abzena subsequently developed a cell line that will now be used to produce the antibody at its GMP manufacturing facility. Abzena will also conduct GMP production of the ADC payload reagent and the conjugation process to create the ADC for initial clinical study.

“Drawing on Abzena’s integrated service offering, this ADC can progress through the preclinical and clinical trial process, with the ultimate goal of developing a new potential cancer treatment.” said John Burt, chief executive officer of Abzena.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters